Display options
Cite
Bushnell DL, Madsen MT, O'cdorisio T, et al. Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res. 2014;4(1):38doi: 10.1186/s13550-014-0038-2.
Bushnell, D. L., Madsen, M. T., O'cdorisio, T., Menda, Y., Muzahir, S., Ryan, R., & O'dorisio, M. S. (2014). Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI research, 4(1), 38. https://doi.org/10.1186/s13550-014-0038-2
Bushnell, David L, et al. "Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors." EJNMMI research vol. 4,1 (2014): 38. doi: https://doi.org/10.1186/s13550-014-0038-2
Bushnell DL, Madsen MT, O'cdorisio T, Menda Y, Muzahir S, Ryan R, O'dorisio MS. Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res. 2014 Dec;4(1):38. doi: 10.1186/s13550-014-0038-2. Epub 2014 Sep 10. PMID: 26116109; PMCID: PMC4452658.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2014 Dec;4(1):38. doi: 10.1186/s13550-014-0038-2. Epub 2014 Sep 10.

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.

EJNMMI research

David L Bushnell, Mark T Madsen, Thomas O'cdorisio, Yusuf Menda, Saima Muzahir, Randi Ryan, M Sue O'dorisio

Affiliations

  1. Department of Radiology, Division of Nuclear Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 52242, USA, [email protected].

PMID: 26116109 PMCID: PMC4452658 DOI: 10.1186/s13550-014-0038-2

Abstract

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient radiation dose to the tumor to result in a high percentage of long-term tumor remissions remains challenging because of the limits imposed on administered activity levels by radiation damage to normal tissues. The goal of this study was to evaluate the dosimetric advantages of adding (131)I meta-iodobenzylguanidine ((131)I-MIBG) to (90)Y DOTA Phe1-Tyr3-octreotide ((90)Y-DOTATOC) in patients with advanced stage midgut NETs.

METHODS: Ten patients were imaged simultaneously with (131)I-MIBG and (111)In-pentetreotide (as a surrogate for (90)Y-DOTATOC) on days 1, 2, and 3 post-administration. Blood samples were obtained at the same time points. Using dosimetry measures from this data and our previously published methodology for calculating optimal combined administered activity levels for therapy, we determined the amount of (131)I-MIBG that could be added to (90)Y-DOTATOC without exceeding normal organ dose limits (marrow and kidneys) along with the expected increase in associated tumor dose, if any.

RESULTS: We found that a median value of 34.6 GBq of (131)I-MIBG could be safely added to (90)Y-DOTATOC (delivered over multiple cycles) by reducing the maximum total deliverable (90)Y-DOTATOC by a median value of 24.5%. Taking this treatment approach, we found that there would be a median increase in deliverable tumor dose of 4,046 cGy in six of the ten subjects. Of note, there were a small number of metastases that were positive for only one or the other of these radiopharmaceuticals within the same subject.

CONCLUSIONS: We conclude that approximately half of the patients with midgut NETs that are eligible for PRRT could reasonably be expected to benefit from the addition of (131)I-MIBG to (90)Y-DOTATOC.

References

  1. Neuroendocrinology. 2012;95(2):157-76 - PubMed
  2. Eur J Nucl Med Mol Imaging. 2004 Oct;31(10 ):1386-92 - PubMed
  3. Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):463-9 - PubMed
  4. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1279-90 - PubMed
  5. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S - PubMed
  6. N Engl J Med. 1983 Oct 20;309(16):937-41 - PubMed
  7. J Clin Endocrinol Metab. 2001 Feb;86(2):895-902 - PubMed
  8. J Clin Oncol. 2012 Apr 1;30(10):1100-6 - PubMed
  9. Eur J Cancer. 1996 Oct;32A(11):1924-32 - PubMed
  10. Br J Cancer. 2008 Mar 25;98(6):1053-8 - PubMed
  11. Cancer Biother Radiopharm. 2003 Aug;18(4):619-25 - PubMed
  12. J Nucl Med. 2005 Jan;46 Suppl 1:99S-106S - PubMed
  13. Acc Chem Res. 2009 Jul 21;42(7):873-80 - PubMed
  14. J Clin Oncol. 2008 May 1;26(13):2124-30 - PubMed
  15. J Nucl Med. 2010 May;51(5):704-12 - PubMed
  16. J Clin Oncol. 2010 Apr 1;28(10):1652-9 - PubMed
  17. Semin Nucl Med. 2010 Mar;40(2):78-88 - PubMed
  18. Semin Nucl Med. 2006 Apr;36(2):147-56 - PubMed
  19. Eur J Nucl Med. 2001 Dec;28(12 ):1743-50 - PubMed
  20. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S93-102 - PubMed
  21. J Nucl Med. 2006 Sep;47(9):1467-75 - PubMed
  22. J Nucl Med. 2006 Feb;47(2):223-33 - PubMed
  23. Br J Cancer. 2013 Apr 16;108(7):1440-8 - PubMed
  24. Theranostics. 2012;2(5):437-47 - PubMed
  25. Nucl Med Biol. 2008 Aug;35 Suppl 1:S35-48 - PubMed
  26. J Nucl Med. 2001 Nov;42(11):1713-21 - PubMed
  27. Technol Cancer Res Treat. 2009 Feb;8(1):51-60 - PubMed
  28. Eur J Nucl Med. 2000 Mar;27(3):273-82 - PubMed
  29. J Nucl Med. 1999 May;40(5):762-7 - PubMed
  30. Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1853-60 - PubMed
  31. J Clin Oncol. 2011 Jun 10;29(17):2416-23 - PubMed
  32. J Nucl Med. 2006 Apr;47(4):660-7 - PubMed
  33. Cancer Biother Radiopharm. 2009 Aug;24(4):469-75 - PubMed
  34. Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):214-22 - PubMed
  35. Pancreas. 2010 Aug;39(6):753-66 - PubMed
  36. Pancreas. 2010 Aug;39(6):735-52 - PubMed
  37. J Nucl Med. 2013 Dec;54(12):2032-8 - PubMed

Publication Types

Grant support